Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.46 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6959357 | 1.00 | BCHE (0.46) | BCHEACHEBACE1MEN1KMT2A | |
| SCHEMBL6966354 | 1.00 | BCHE (0.46) | BCHEACHEBACE1MEN1KMT2A | |
| SCHEMBL8441694 | 0.85 | ESR1 (0.39) | — | |
| SCHEMBL10606861 | 0.81 | MCHR1 (0.55) | BCHEMCHR1PRMT5WDR77 | |
| SCHEMBL6963639 | 0.79 | MCHR1 (0.55) | MCHR1PRMT5WDR77 | |
| SCHEMBL10608988 | 0.78 | MEN1 (0.59) | BCHEACHEBACE1MEN1KMT2A | |
| Oxalic Acid SCHEMBL10605600 | 0.77 | MCHR1 (0.51) | BCHEMCHR1PRMT5WDR77 | |
| SCHEMBL8257881 | 0.77 | PDE3B (0.36) | — | |
| SCHEMBL10610498 | 0.75 | ROCK1 (0.55) | MCHR1PRMT5WDR77 | |
| SCHEMBL13460892 | 0.74 | BCHE (0.58) | BCHEACHEBACE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0863136-B1 | Derivatives of azetidine and pyrrolidine | AKZO NOBEL NV (NL) | 2003-09-24 | — | — | EP | disclosed |
| US-6403573-B1 | BICYCLIC-CARBO OR HETERO OXY OR BICYCLIC CARBO OR HETERO SULFIDE CONTAINING PYRROLIDINE/AZETIDINE DERIVATIVES USED AS ANTIDEPRESSANT OR PREVENTING SEROTONIN-RELATED DISEASES | AKZO NOBEL N.V. (NL) | 2002-06-11 | — | — | US | disclosed |
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | MERCK SHARP & DOHME B.V. (NL) | 2002-04-04 | — | — | US | disclosed |
| US-6281243-B1 | ANTIDEPRESSANTS, ANTISEROTONINE AGENT | AKZO NOBEL N.V. (NL) | 2001-08-28 | — | — | US | disclosed |
| EP-0863136-A1 | Derivatives of azetidine and pyrrolidine | Akzo Nobel N.V. (NL) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | TPH1, TPH2, HTR1D | BCHE 1439/4885ACHE 790/4885BACE1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.